Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia

Drugs

Volumn 76, Issue 7, 2016, Pages 759-777

  Vijayakumar, Dhanya ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; BACLOFEN; BOTULINUM TOXIN; BUDIPINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; CVT 301; DEXTROMETHORPHAN; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; IDAZOXAN; LEVETIRACETAM; LEVODOPA; MEMANTINE; NABILONE; ODM 101; PRAMIPEXOLE; PRELADENANT; QUETIAPINE; RILUZOLE; ROPINIROLE; ROTIGOTINE; TALAMPANEL; TETRABENAZINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONISAMIDE; ANTIPARKINSON AGENT;

BLOOD BRAIN BARRIER; BRAIN DEPTH STIMULATION; BREATHING MUSCLE; CLINICAL FEATURE; DISEASE COURSE; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG HALF LIFE; DYSKINESIA; DYSTONIA; FOOT MALFORMATION; HAND MALFORMATION; HUMAN; LEVODOPA-INDUCED DYSKINESIA; MULTICENTER STUDY (TOPIC); ONSET AGE; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; WAKEFULNESS; DYSKINESIA, DRUG-INDUCED;

AMANTADINE; ANTI-DYSKINESIA AGENTS; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84964335015     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-016-0566-3     Document Type: Review

References (163)

1. Loonen AJMAJ. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 2013;18(1):15.
2. Walters AS, McHale D, Sage JI, Hening WA, Bergen M. A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia, and l-dopa-induced chorea. Clin Neuropharmacol. 1990;13(3):236-40.
3. Ramirez-Castaneda J, Jankovic J. l-Dopa dyskinesias. In: Friedman JH, editor. Medication induced movement disorders. Cambridge University Press; 2015. p. 110-81.
4. Pilleri M, Antonini A. Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease. Expert Opin Drug Saf. 2015;14(2):281-94.
5. Xie T, Guan R, Staisch J, Towle VL, Warnke P. Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS. Neurology. 2015;85(5):479-80.
6. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005;20(11):S11-6.
7. Prashanth LK, Fox S, Meissner WG. l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment. Int Rev Neurobiol. 2011;98:31-54.
8. Encarnacion EV, Hauser RA. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Eur Neurol. 2008;60(2):57-66.
9. Wickremaratchi MM, Knipe MD, Sastry BS, Morgan E, Jones A, Salmon R, et al. The motor phenotype of Parkinson's disease in relation to age at onset. Mov Disord. 2011;26(3):457-63.
10. Mehanna R, Moore S, Hou JG, Sarwar AI, Lai EC. Comparing clinical features of young onset, middle onset and late onset Parkinson's disease. Parkinsonism Relat Disord. 2014;20(5):530-4.
11. Jankovic J. Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord. 2010;25(5):527-8 (Epub 2010/04/29).
12. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol. 1996;39(1):37-45.
13. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-508.
14. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin Neuropharmacol. 2000;23(1):34-44 (Epub 2000/02/22).
15. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-l-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190-9.
16. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol. 2006;63(2):205-9 (Epub 2006/02/16).
17. Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014;71(4):499-504.
18. Nicoletti A, Mostile G, Nicoletti G, Arabia G, Iliceto G, Lamberti P, et al. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease. J Neurol. 2016;10:10.
19. Sharma JC, Bachmann CG, Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat Disord. 2010;16(8):490-7 (Epub 2010/07/06).
20. Lee JY, Cho J, Lee EK, Park SS, Jeon BS. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease. Mov Disord. 2011;26(1):73-9.
21. Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, et al. Which dyskinesia scale best detects treatment response? Mov Disord. 2013;28(3):341-6.
22. Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, et al. Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord. 2011;26(13):2371-80.
23. Papapetropoulos SS. Patient diaries as a clinical endpoint in Parkinson's disease clinical trials. CNS Neurosci Ther. 2012;18(5):380-7.
24. Fahn S. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord. 2015;30(1):4-18.
25. Brod LS, Aldred JL, Nutt JG. Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease. Mov Disord. 2012;27(6):750-3.
26. Linazasoro G, Antonini A, Maguire RP, Leenders KL. Pharmacological and PET studies in patient's with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications. J Neural Transm. 2004;111(4):497-509.
27. Hong JY, Oh JS, Lee I, Sunwoo MK, Ham JH, Lee JE, et al. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology. 2014;82(18):1597-604.
28. Jankovic J, Bressman S, Dauer W, Kang UJ. Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. Mov Disord. 2015;30(14):1862-9.
29. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of l-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev. 2013;65(1):171-222.
30. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2(8):577-88.
31. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5(8):677-87.
32. Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, et al. Pathophysiology of l-dopa-induced motor and non-motor complications in Parkinson's disease. Prog Neurobiol. 2015;132:96-168.
33. Lee J, Zhu WM, Stanic D, Finkelstein DI, Horne MH, Henderson J, et al. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain. 2008;131(Pt 6):1574-87.
34. LeWitt PA. Levodopa therapy for Parkinson's disease: pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30(1):64-72.
35. Tomiyama M. Adenosine receptors and dyskinesia in pathophysiology. Int Rev Neurobiol. 2014;119:117-26.
36. Nutt JG, Carter JH. Apomorphine can sustain the long-duration response to l-DOPA in fluctuating PD. Neurology. 2000;54(1):247-50.
37. Herz DM, Haagensen BN, Christensen MS, Madsen KH, Rowe JB, Lokkegaard A, et al. Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans. Brain. 2015;138(Pt 6):1658-66.
38. Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Mov Disord. 2015;30(6):788-95.
39. Lee JY, Seo S, Lee JS, Kim HJ, Kim YK, Jeon BS. Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease. Neurology. 2015;85(10):853-60.
40. Huot P, Hutchison WD. Serotonin/dopamine transporter ratio as a predictor of l-dopa-induced dyskinesia. Neurology. 2015;85(10):840-1 (Epub 2015/08/09).
41. Fox SH, editor. Parkinson's disease: motor symptoms; motor complications and current treatments. Orlando: AAN Breakthrough Course; 2016.
42. Mazzucchi S, Frosini D, Bonuccelli U, Ceravolo R. Current treatment and future prospects of dopa-induced dyskinesias. Drugs Today. 2015;51(5):315-29.
43. Jankovic J, Poewe W. Therapies in Parkinson's disease. Curr Opin Neurol. 2012;25(4):433-47.
44. Xie CL, Zhang YY, Wang XD, Chen J, Chen YH, Pa JL, et al. Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis. Neurol Sci. 2015;36(8):1319-29.
45. Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196-205.
46. Haaxma CA, Horstink MW, Zijlmans JC, Lemmens WA, Bloem BR, Borm GF. Risk of disabling response fluctuations and dyskinesias for dopamine agonists versus levodopa in parkinson's disease. J Parkinsons Dis. 2015;5(4):847-53.
47. Rascol O, Perez-Lloret S, Ferreira JJ. New treatments for levodopa-induced motor complications. Mov Disord. 2015;30(11):1451-60.
48. Nomoto M, Kubo S, Nagai M, Yamada T, Tamaoka A, Tsuboi Y, et al. A randomized controlled trial of subcutaneous apomorphine for parkinson disease: a repeat dose and pharmacokinetic study. Clin Neuropharmacol. 2015;38(6):241-7.
49. Gottwald MD, Aminoff MJ. Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol. 2011;69(6):919-27.
50. Bajenaru O, Ene A, Popescu BO, Szasz JA, Sabau M, Muresan DF, et al. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience. J Neural Transm. 2015;23:23.
51. Timpka J, Fox T, Fox K, Honig H, Odin P, Martinez-Martin P, et al. Improvement of dyskinesias with l-dopa infusion in advanced Parkinson's disease. Acta Neurol Scand. 2015;11(10):12483.
52. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord. 2007;22(10):1379-89.
53. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342(20):1484-91.
54. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011;26(3):23829.
55. Utsumi H, Okuma Y, Kano O, Suzuki Y, Iijima M, Tomimitsu H, et al. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease. Int Med. 2013;52(3):325-32.
56. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044-53.
57. Parkinson Study Group CCI. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009;66(5):563-70 (Epub 2009/05/13).
58. Batla A, Stamelou M, Mencacci N, Schapira AH, Bhatia KP. Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease. Mov Disord. 2013;28(8):1159-60. doi: 10.1002/mds.25318 (Epub 2013 Feb 5).
59. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22(16):2409-17.
60. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68(14):1108-15.
61. Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord. 2010;25(7):858-66.
62. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64(5):676-82.
63. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513-20.
64. Giladi N, Ghys L, Surmann E, Boroojerdi B, Jankovic J. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism Relat Disord. 2014;20(12):1345-51.
65. Tintner R, Manian P, Gauthier P, Jankovic J. PLeuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for parkinson disease. Arch Neurol. 2005;62(8):1290-5.
66. Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346-56.
67. Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord. 2014;20(2):142-8.
68. Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism Relat Disord. 2013;19(3):339-45.
69. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141-9.
70. Antonini A, Yegin A, Preda C, Bergmann L, Poewe W. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015;21(3):231-5.
71. Calandrella D, Romito LM, Elia AE, Del Sorbo F, Bagella CF, Falsitta M, et al. Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease. Neurology. 2015;84(16):1669-72.
72. Snow BJ, Macdonald L, McAuley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2000;23(2):82-5.
73. Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014;82(4):300-7.
74. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord. 2010;25(10):1357-63.
75. Vijverman AC, Fox SH. New treatments for the motor symptoms of Parkinson's disease. Expert Rev Clin Pharmacol. 2014;7(6):761-77.
76. Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology. 2004;62(3):381-8.
77. Pahwa RR. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-95.
78. Hack N, Fayad SM, Monari EH, Akbar U, Hardwick A, Rodriguez RL, et al. An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. PloS One. 2014;9(3):e91545. doi: 10.1371/journal.pone.0091545
79. Du H, Nie S, Chen G, Ma K, Xu Y, Zhang Z, et al. Levetiracetam ameliorates l-DOPA-induced dyskinesia in hemiparkinsonian rats inducing critical molecular changes in the striatum. Parkinsons Dis. 2015;253878(10):27.
80. Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grimee R, et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol. 2004;485(1-3):159-64.
81. Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, et al. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther. 2004;310(1):386-94.
82. Tousi B, Subramanian T. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease. Parkinsonism Relat Disord. 2005;11(5):333-4.
83. Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2005;20(9):1205-9.
84. Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2011;26(2):264-70.
85. Lyons KE, Pahwa R. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol. 2006;29(3):148-53.
86. Silverdale MA, Nicholson SL, Crossman AR, Brotchie JM. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov Disord. 2005;20(4):403-9.
87. Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. J Neurochem. 2010;114(2):499-511.
88. Kobylecki C, Burn DJ, Kass-Iliyya L, Kellett MW, Crossman AR, Silverdale MA. Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease. Parkinsonism Relat Disord. 2014;20(4):452-5.
89. Murata M, Hasegawa K, Kanazawa I, Fukasaka J, Kochi K, Shimazu R. Zonisamide improves wearing-off in Parkinson's disease: a randomized, double-blind study. Mov Disord. 2015;30(10):1343-50.
90. Katzenschlager R, Manson AJ, Evans A, Watt H, Lees AJ. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J Neurol Neurosurg Psychiatry. 2004;75(2):295-7.
91. Tronci E, Fidalgo C, Zianni E, Collu M, Stancampiano R, Morelli M, et al. Effect of memantine on l-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. Neuroscience. 2014;265:245-52.
92. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11(11):1509-23.
93. Brusa L, Orlacchio A, Stefani A, Galati S, Pierantozzi M, Iani C, et al. Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease. Funct Neurol. 2013;28(2):101-5.
94. Paquette MA, Martinez AA, Macheda T, Meshul CK, Johnson SW, Berger SP, et al. Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors. Eur J Neurosci. 2012;36(9):3224-34.
95. Verhagen Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology. 1998;51(1):203-6.
96. Chase TN, Oh JD, Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol. 2000;247(2):II36-42.
97. Bargiotas P, Konitsiotis S. Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments. Neuropsychiatr Dis Treat. 2013;9:1605-17.
98. Avanir Pharmaceuticals. Safety and Efficacy of AVP-923 in the treatment of levodopa-induced dyskinesia in Parkinson's disease patients (LID in PD): NCT01767129. 2015.
99. Bara-Jimenez W, Dimitrova TD, Sherzai A, Aksu M, Chase TN. Glutamate release inhibition ineffective in levodopa-induced motor complications. Mov Disord. 2006;21(9):1380-3.
100. Krack P, Pollak P, Limousin P, Benazzouz A, Deuschl G, Benabid AL. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. Brain. 1999;122(Pt 6):1133-46.
101. Munhoz RP, Okun MS. Levodopa-induced dyskinesia in Parkinson's disease. London: Springer-Verlag; 2014.
102. Baizabal-Carvallo J, Jankovic J. Movement disorders induced by deep brain stimulation. Parkinsonism Relat Disord. 2016;25:1-9. doi: 10.1016/j.parkreldis.2016.01.014.
103. Pollak P. Deep brain stimulation for Parkinson's disease - patient selection. Handb Clin Neurol. 2013;116:97-105.
104. Anderson VC, Burchiel KJ, Hogarth P, Favre J, Hammerstad JP. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol. 2005;62(4):554-60.
105. Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med. 2010;362(22):2077-91.
106. Oyama G, Foote KD, Jacobson CE, Velez-Lago F, Go C, Limotai N, et al. GPi and STN deep brain stimulation can suppress dyskinesia in Parkinson's disease. Parkinsonism Relat Disord. 2012;18(7):814-8.
107. Kim JH, Chang WS, Jung HH, Chang JW. Effect of subthalamic deep brain stimulation on levodopa-induced dyskinesia in Parkinson's disease. Yonsei Med J. 2015;56(5):1316-21.
108. Oyama G, Foote KD, Iyer SS, Zeilman P, Hwynn N, Jacobson CE, et al. Unilateral GPi-DBS as a treatment for levodopa-induced respiratory dyskinesia in Parkinson disease. Neurologist. 2011;17(5):282-5.
109. Li Q, Qian ZM, Arbuthnott GW, Ke Y, Yung WH. Cortical effects of deep brain stimulation: implications for pathogenesis and treatment of Parkinson disease. JAMA Neurol. 2014;71(1):100-3.
110. Metman LV, Slavin KV. Advances in functional neurosurgery for Parkinson's disease. Mov Disord. 2015;30(11):1461-70.
111. Lotia M, Jankovic J. New and emerging therapies in PD. Expert Opin Pharmacother. 2016;19:1-15.
112. LeWitt PFH, Giladi N, et al. Poster presentation: accordion pill carbidopa-levodopa for improved symptomatic treatment of advanced Parkin-son's disease. Mov Disord. 2012;27(S1):S1-523.
113. Poewe W, Antonini A. Novel formulations and modes of delivery of levodopa. Mov Disord. 2015;30(1):114-20.
114. Giladi N, Caraco Y, Gurevich T, Djaldetti R, Cohen Y, Yacobi-Zeevi O, Oren S, Kieburtz K, Warren Olanow C. Stable levodopa plasma levels with ND0612 (levodopa/carbidopa for subcutaneous infusion) in Parkinson's disease (PD) patients with motorfluctuations. Abstract presented at 19th international congress of Parkinson's disease and movement disorders, San Diego; 2015.
115. Yacoby-Zeevi O, LeWitt PA. Maintenance of constant steady state therapeutic plasma concentrations of levodopa following its continuous subcutaneous administration with carbidopa. MDS abstract from the 16th international congress of Parkinson's disease and movement disorders, vol. 2, Dublin, Ireland, 17-21 June 2012.
116. Trenkwalder C, Chaudhuri KR, Garcia Ruiz PJ, LeWitt P, Katzenschlager R, Sixel-Doring F, et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease-Clinical practice recommendations. Parkinsonism Relat Disord. 2015;21(9):1023-30.
117. LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology. 2004;62(6 Suppl 4):S8-11.
118. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998;64(5):573-6.
119. Kanovsky P, Kubova D, Bares M, Hortova H, Streitova H, Rektor I, et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord. 2002;17(1):188-91.
120. Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord. 2005;20(2):151-7.
121. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord. 2002;17(6):1235-41.
122. Valldeoriola F, Puig-Junoy J, Puig-Peiro R. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study. J Med Econ. 2013;16(2):191-201.
123. Cenci MA, Lindgren HS. Advances in understanding l-DOPA-induced dyskinesia. Curr Opin Neurobiol. 2007;17(6):665-71.
124. Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Brain. 2015;138(Pt 4):963-73.
125. Jimenez-Urbieta H, Gago B, de la Riva P, Delgado-Alvarado M, Marin C, Rodriguez-Oroz MC. Dyskinesias and impulse control disorders in Parkinson's disease: from pathogenesis to potential therapeutic approaches. Neurosci Biobehav Rev. 2015;56:294-314.
126. ADAMAS. Adamas announces positive top-line phase 3 results of ADS-5102 for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Globe Newswire. 2015. http://ir.adamaspharma.com/releasedetail.cfm?releaseid=948032. Accessed 29 Mar 2016.
127. Benarroch EE. Adenosine and its receptors: multiple modulatory functions and potential therapeutic targets for neurologic disease. Neurology. 2008;70(3):231-6.
128. Sharma S, Singh S, Sharma V, Singh VP, Deshmukh R. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies. Biomed Pharmacother. 2015;70:283-93.
129. Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, et al. Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord. 2013;28(3):380-3.
130. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011;10(3):221-9.
131. Hauser RA, Stocchi F, Rascol O, Huyck SB, Capece R, Ho TW, et al. Preladenant as an adjunctive therapy with levodopa in parkinson disease: two randomized clinical trials and lessons learned. JAMA Neurol. 2015;2:1-10.
132. Mizuno Y, Kondo T. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord. 2013;28(8):1138-41.
133. Vorovenci RJ, Antonini A. The efficacy of oral adenosine A2A antagonist istradefylline for the treatment of moderate to severe Parkinson's disease. Expert Rev Neurother. 2015;15(12):1383-90.
134. Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, et al. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014;13(8):767-76.
135. Lewitt PA, Hauser RA, Lu M, Nicholas AP, Weiner W, Coppard N, et al. Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology. 2012;79(2):163-9.
136. Hauser RA, Bronzova J, Sampaio C, Lang AE, Rascol O, Theeuwes A, et al. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. Eur Neurol. 2009;62(1):40-8.
137. Sampaio C, Bronzova J, Hauser RA, Lang AE, Rascol O, van de Witte SV, et al. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Mov Disord. 2011;26(8):1464-76.
138. Rascol O, Bronzova J, Hauser RA, Lang AE, Sampaio C, Theeuwes A, et al. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord. 2012;18(4):370-6.
139. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Mov Disord. 2014;29(10):1273-80.
140. Schapira AHV, Fox SH, Hauser RA, Jankovic J, Jost W, Kulisevsky J, Pahwa R, Poewe W, Lucini V, Anand R. Safinamide significantly improves responder rates in fluctuating Parkinson's disease (PD) patients as add-on to levodopa (SETTLE). 17th international congress of Parkinson's disease and movement disorders, Sydney, Australia, 16-20 June, 2013.
141. Quik M, O'Leary K, Tanner CM. Nicotine and Parkinson's disease: implications for therapy. Mov Disord. 2008;23(12):1641-52.
142. Quik M, Bordia T, Zhang D, Perez XA. Nicotine and nicotinic receptor drugs: potential for Parkinson's disease and drug-induced movement disorders. Int Rev Neurobiol. 2015;124:247-71.
143. Neuraltus Pharmaceuticals I. Randomized, double-blind, parallel group, placebo controlled safety, tolerability and efficacy study of NP002 in subjects with idiopathic Parkinson's disease with dyskinesias due to levodopa therapy. ClinicalTrials.gov U.S. National Institutes of Health; 2011 [updated September 26, 2011; cited 2015 September 8]; August 11, 2009: [(website on the Internet)]. Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT00957918?view=results.
144. Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, et al. A placebo-controlled trial of AQW051 in patients with moderate to severe levodopa-induced dyskinesia. Mov Disord. 2016;15(10):26569.
145. Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556-63.
146. Kluger B, Triolo P, Jones W, Jankovic J. The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015;30(3):313-27.
147. Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci. 2003;18(6):1607-14.
148. van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. Faseb J. 2005;19(9):1140-2.
149. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology. 2001;57(11):2108-11.
150. Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. 2004;63(7):1245-50.
151. Potts LF, Park ES, Woo JM, Dyavar Shetty BL, Singh A, Braithwaite SP, et al. Dual kappa-agonist/mu-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease. Ann Neurol. 2015;77(6):930-41.
152. Brusa L, Versace V, Koch G, Iani C, Stanzione P, Bernardi G, et al. Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson's disease. Clin Neurophysiol. 2006;117(9):1917-21.
153. Filipovic SR, Rothwell JC, van de Warrenburg BP, Bhatia K. Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2009;24(2):246-53.
154. Sayin S, Cakmur R, Yener GG, Yaka E, Ugurel B, Uzunel F. Low-frequency repetitive transcranial magnetic stimulation for dyskinesia and motor performance in Parkinson's disease. J Clin Neurosci. 2014;21(8):1373-6.
155. MJFF Research Grant. A study to evaluate feasibility, safety and preliminary efficacy of magnetic resonance image guided focused ultrasound for the treatment of Parkinson's disease dyskinesia. The Michael J Fox Foundation for Parkinson's Research [Internet]. 2013. https://www.michaeljfox.org/foundation/grant-detail.php?grant-id=1111. Accessed 29 Mar 2016.
156. Bezard E, Tronci E, Pioli EY, Li Q, Porras G, Bjorklund A, et al. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord. 2013;28(8):1088-96.
157. Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007;22(2):179-86.
158. Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol. 2004;27(2):58-62.
159. Nutt JG, Gunzler SA, Kirchhoff T, Hogarth P, Weaver JL, Krams M, et al. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov Disord. 2008;23(13):1860-6.
160. Wu SS, Frucht SJ. Treatment of Parkinson's disease: what's on the horizon? CNS Drugs. 2005;19(9):723-43.
161. Duty S. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease. CNS Drugs. 2012;26(12):1017-32.
162. Manson AJ, Iakovidou E, Lees AJ. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov Disord. 2000;15(2):336-7.
163. Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, Thalamas C, et al. Idazoxan, an alpha-2 antagonist, and l-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord. 2001;16(4):708-13.